AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03210532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan + Amlodipine + Rosuvastatin
Description: Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
Study NCT03210532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan + Amlodipine
Description: Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
Study NCT03210532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan + Rosuvastatin
Description: Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
Study NCT01680614 — intervention group
Intervention type: BEHAVIORAL
Intervention: CASI
Study NCT02141555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol
Description: Misoprostol inserted into vagina
Study NCT02141555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Misoprostol
Description: Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
Study NCT02641834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian diet
Description: 7-days dietary profile with an isocaloric Vegetarian diet for 3 months
Study NCT02641834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: 7-days dietary profile with an isocaloric Vegetarian diet for 3 months
Study NCT02641834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: 7-days dietary profile with an isocaloric Mediterranean diet for 3 months
Study NCT02641834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: 7-days dietary profile with an isocaloric Mediterranean diet for 3 months
Study NCT02312843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise/Aerobic
Study NCT02312843 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise/Stretching
Study NCT03365648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lertal® + standard therapy
Description: Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~* Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~* Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~* Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine.
Study NCT03365648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + standard therapy
Description: Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine
Study NCT04547751 — intervention group
Intervention type: OTHER
Intervention: targeted high-resolution mass spectrometry
Description: difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry
Study NCT01991795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg bd taken orally as tablets
Study NCT01991795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor placebo
Description: Ticagrelor placebo bd taken orally as tablets
Study NCT00769769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
Study NCT00769769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
Study NCT01721902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous CD133+ Bone Marrow Stem Cells
Description: Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
Study NCT01721902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carrier Solution
Description: Intra-myocardial injection of carrier solution
Study NCT03076879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting participation in cervical cancer screening
Description: Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training.
Study NCT05372159 — intervention group
Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study
Study NCT01613833 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood drawn for A2M levels to be assayed at Cytonics
Study NCT01613833 — intervention group
Intervention type: PROCEDURE
Intervention: Joint Aspirate Harvest
Description: Joint aspirate harvested for A2M levels to be assayed at Cytonics
Study NCT01413802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous nerve monitoring
Description: Continuous nerve monitoring is performed during thyroid surgery.
Study NCT03012737 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trilogy 100 ® (Philips Respironics)
Description: Trilogy 100 ® (Philips Respironics) on MPV mode.
Study NCT03980223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate Delayed-Release 200 mg
Description: 200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
Study NCT04043026 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: Any statin therapy
Study NCT03229499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Study NCT03229499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: matching placebo tablet
Study NCT01214278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rTG
Description: EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
Study NCT01214278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GArTG
Description: EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
Study NCT01214278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE
Description: EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
Study NCT01214278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL
Description: DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
Study NCT01471626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polysomnograph Dream and Sleep Box
Description: Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
Study NCT02920658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAVS Naphthalan
Study NCT02920658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Betamethasone dipropionate
Study NCT02425085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-endodiathermy retinectomy
Description: patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
Study NCT02425085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: relaxing retinectomy
Description: patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
Study NCT00127803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vaccine diluent)
Description: 0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
Study NCT00127803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: 0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
Study NCT04812158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard ankle physiotherapy or rehabilitation for chronic ankle instability
Description: 6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
Study NCT04812158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard ankle physiotherapy or rehabilitation for chronic ankle instability
Description: 6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
Study NCT01180062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
Study NCT01180062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2
Description: Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
Study NCT01180062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost SR insert
Description: Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
Study NCT01211171 — intervention group
Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study NCT02478827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
Study NCT03169439 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Irreversible electroporation
Description: minimal invasive ablative technique for tumors
Study NCT02640209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART 19
Description: The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
Study NCT02715453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention on frailty
Description: Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~* Nutritional evaluation and intervention after randomization and regularly during follow-up~* Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~* Psychiatrist or psychologist assistance for 1 year after discharge
Study NCT03755817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENAR application
Description: Active SCENAR application on the painful area
Study NCT03755817 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SCENAR application with the device off
Description: Placebo SCENAR application on the painful area
Study NCT01154660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal Volume
Description: observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
Study NCT01154660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal Volume
Description: observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
Study NCT01918228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talks about what science says about LBP
Description: Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
Study NCT01550926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 mg orlistat
Description: 2 X60 mg capsule
Study NCT01550926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg orlistat
Description: 60 mg orlistat
Study NCT01550926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat experimental dose
Description: experimental
Study NCT03982537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl-L-Cysteine dietary supplement
Description: Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
Study NCT03982537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy and Radiation
Description: Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
Study NCT03982537 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Chemotherapy and Radiation
Description: Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
Study NCT04131972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REGENERA
Description: REGENERA breast implant
Study NCT03721354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA vs PSV - TCCD
Description: Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker.
Study NCT02239289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Idem as described in the arm section (above)
Study NCT02542527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid filled breast pump
Description: breast milk pumping with a fluid filled breast pump
Study NCT02057341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule
Study NCT00862992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg
Study NCT00862992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 6 mg
Study NCT00862992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 12.5 mg
Study NCT02912936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic medium chain triglyceride drink (MCT drink)
Description: 10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
Study NCT02912936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
Study NCT02071498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillbox app named ALICE
Description: Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
Study NCT02071498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral and written information
Description: oral and written information about the most common errors of patients
Study NCT02157090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Patch SOS (Hansaplast®)
Study NCT02157090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herpes vesicle patch of Compeed®
Study NCT01260948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: 10 mg Orally Disintegrating Tablet
Study NCT01260948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Orally Disintegrating Tablet
Study NCT00640289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrogammin P
Description: Prophylaxis treatment
Study NCT00910585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching, providing social support
Description: Active telephone and in person coaching
Study NCT00910585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching, providing social support
Description: Active telephone and in person coaching
Study NCT03922373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: Benzonatate 100mg
Description: Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
Study NCT03922373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: Benzonatate 200mg
Description: Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
Study NCT03922373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C: Benzonatate 400mg
Description: Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
Study NCT01685437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
Study NCT03279575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Shift
Description: Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
Study NCT03279575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graveyard Shift
Description: Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
Study NCT03279575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
Study NCT03279575 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Physicians in this arm will serve as a no-contact control group.
Study NCT04280952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONVIVO
Description: tumor tissue with the CONVIVO system
Study NCT01164475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Study NCT01164475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Study NCT01164475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Plerixafor